The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
-
BUSINESS Big 3 Generic Firms Log 5.9% Sales Increase in FY2019, with Contraction in Overseas Business: Jiho Tally
June 9, 2020
-
ORGANIZATION Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
June 8, 2020
-
ACADEMIA Nobel Laureate Honjo Taking Ono to Court, Demands 22.6 Billion Yen
June 8, 2020
-
ACADEMIA Remdesivir Not Used as Severe Cases Decreased, Avigan/Alvesco Given to Several Dozen Patients: TMDU Hospital
June 5, 2020
-
BUSINESS Kyowa Kirin Looks to Make Crysvita 1st In-House Blockbuster, Sees 100 Billion Yen Target “Not Unachievable”
June 5, 2020
-
ORGANIZATION API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
June 4, 2020
-
BUSINESS Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
-
BUSINESS 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally
June 2, 2020
-
BUSINESS 6 Japan Drug Makers Net 20% Growth in China Biz Despite COVID-19 Woes
June 1, 2020
-
REGULATORY Oral Semaglutide Clears MHLW Panel, Now in Line for June Approval
June 1, 2020
-
ACADEMIA Japan to Join NIH’s Remdesivir-Baricitinib Combo Trial for COVID-19
June 1, 2020
-
BUSINESS Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
-
ACADEMIA Nagasaki Univ. to Launch Clinical Trial for Nelfinavir for COVID-19
May 28, 2020
-
BUSINESS Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
-
BUSINESS Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
-
REGULATORY Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
-
ACADEMIA Discontinued HIV Med Nelfinavir Hits Limelight as Potential COVID-19 Treatment
May 26, 2020
-
REGULATORY Japan Govt to Give Up on May-End Goal for Avigan Approval
May 26, 2020
-
REGULATORY MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…